Dec 9 (Reuters) - CVS Health (CVS) on Tuesday forecast 2026 profit above Wall Street estimates and this year's projected earnings, signalling steady progress in the health conglomerate's turnaround plan.
CVS stock rose 5% in early trading on Tuesday.
The company in October projected double-digit earnings growth for 2026 after raising its 2025 profit forecast for the third time.
"We are closing out 2025 with meaningful momentum across our businesses and we expect another year of strong earnings growth in 2026," said Chief Financial Officer Brian Newman on Tuesday.
The company forecast 2026 adjusted profit to be in the range of $7.00 to $7.20 per share, compared with analysts' average estimate of $7.16, according to data compiled by LSEG.
It, however, expects total revenue of at least $400 billion next year, below analysts' average estimate of $419.26 billion.
CVS also raised its 2025 adjusted profit forecast to $6.60 to $6.70 per share from $6.55 to $6.65 previously.
(Reporting by Sneha S K in Bengaluru; Editing by Shinjini Ganguli)
latest_posts
- 1
Windows to the Previous: An Excursion Through the World's Notable Engineering - 2Japan prepares to restart world's biggest nuclear plant, 15 years after Fukushima
- 3Instructions to Augment the Presentation of Your Kona SUV
- 4NASA loses contact with its Maven spacecraft orbiting Mars for the past decade
- 5Building an Individual Brand: Illustrations from Forces to be reckoned with
- Hypothermia claims newborn in Gaza and more babies are at risk, doctor says
- Oil rises above $115 and Asia stocks slide as Iran war escalates
- Iranian rockets hit Tel Aviv area, injuring six
- A 'rampaging lion' nebula roars to life in a stunning deep-space photo
- Ancient mass grave discovered in water cistern during Tel Azekah excavations
- Top notch Remote Earphones for Audiophiles
- Surveys of 6 Hot Savvy Beds
- The most effective method to Alter Your Kona SUV for Greatest Solace and Comfort
- James Webb Space Telescope watches our Milky Way galaxy's monster black hole fire out a flare
